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GLUCOSAMINE AND CHONDROITIN FOR KNEE OSTEOARTHRITIS: A
DOUBLE BLIND RANDOMISED CONTROLLED CLINICAL TRIAL
EVALUATING SINGLE AND COMBINATION REGIMENS
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R.O. Day yy. y Faculty of Hlth.Sci., Univ. of Sydney, Lidcombe, Australia;
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xCovance Pty Ltd, Macquarie Park, Australia; k The George Inst. for
Global Hlth., Camperdown, Australia; { Inst. of Bone and Joint Res., Univ.
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Purpose: Glucosamine and chondroitin are dietary supplements fre-
quently utilised by people with chronic joint pain. Evidence for symp-
tomatic or structural beneﬁt is inconclusive.
Methods: A double-blind randomised placebo-controlled clinical trial.
A total of 605 people aged 45 to 75 years with chronic knee pain and
medial tibio-femoral compartment narrowing were randomised to take
once daily: glucosamine sulfate potassium chloride1500 mg (n ¼ 152),
low molecular weight bovine-derived chondroitin sulfate 800 mg (n ¼
151), both dietary supplements (n ¼ 151) or matching placebo capsules
(n¼ 151) for two years. The primary hypotheses were that these dietary
supplements would result in reduced joint space narrowing at two
years and reduced knee pain over one year, compared to placebo. Joint
space width wasmeasured from digitised radiographs. Knee pain (0-10)
was reported daily in a Participant Diary for seven days every two
months.
Results: The mean (sd) age and BMI of this study sample was 60.5 (8.1)
years and 29.0 (5.5). At baseline, the mean (sd) medial joint space width
was 3.8 (1.0) mm and knee pain 4.7 (2.4); most evaluated knees (52%)
had early radiographic disease (Kellgren and Lawrence grade <2). Two-
year fol1ow-up in each of the allocation groups ranged from 81-85%. At
two years, mean (sd) medial joint space narrowing in the placebo group
was 0.22 (0.33) mm. After adjusting for gender, BMI, structural disease
severity and Heberdens nodes, allocation to the glucosamine-chon-
droitin combination resulted in a signiﬁcantly reduced two year joint
space narrowing compared to placebo [mean difference 0.10 mm (95%
conﬁdence interval: 0.002 to 0.20 mm); no signiﬁcant structural effect
for the single treatment allocations was detected. All allocation groups
demonstrated reduced knee pain over the ﬁrst year, with no signiﬁcant
between-group differences (p ¼ 093). However, our study appeared to
demonstrate a trend for a slightly greater knee pain reduction for the
active treatment allocations during the second year, compared to pla-
cebo. There were no signiﬁcant effects demonstrated for any of the
secondary outcome measures. Only 34 (6%) participants withdrew from
study treatment due to adverse medical events; these events were
balanced between the allocation groups.
Conclusion: The combination of glucosamine sulfate with chon-
droitin sulfate for two years resulted in a signiﬁcantly reduced joint
space narrowing among these study participants with mostly mild
structural disease severity. While all allocation groups demonstrated
reduced knee pain over the study period, none of the treatment
allocation groups demonstrated signiﬁcant symptomatic beneﬁt
above placebo.
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A SYSTEMATIC REVIEW AND META-ANALYSIS OF BIOMECHANICAL
AND CLINICAL EFFECTS OF VALGUS KNEE BRACING
R. Moyer, T. Birmingham, K. Marriott, D. Bryant, K. Leitch, J. Gifﬁn.
Western Univ., London, ON, Canada
Purpose: Clinical practice guidelines include knee braces designed to
redistribute loads across the knee, decrease pain and improve function
for patients with lower limbmalalignment and knee osteoarthritis (OA).
Despite reviewing the same literature, some guidelines support the use
of valgus knee bracing as an appropriate treatment for medial knee OA,
while others suggest inconclusive evidence to support brace use. The
objective of this systematic review andmeta-analysis was to investigate
the biomechanical effects, patient-reported outcomes, complications
and compliance with valgus brace use for medial compartment
knee OA.
Methods: Adhering to the PRISMA guidelines for systematic reviews,
ﬁve electronic databases were searched from their inception toFebruary 2013. Two reviewers independently determined study eligi-
bility, rated study quality and extracted data. Articles were ﬁrst cate-
gorized as being primarily biomechanical or clinical. We deﬁned
biomechanical articles as laboratory studies that repeated tests with
and without wearing a valgus brace. Clinical studies were further
categorized by study design including observational cohorts and
randomized clinical trials. Pooled estimates for each meta-analysis
were obtained using a random effects model. Heterogeneity was tested
using I2. For biomechanical outcome measures, standardized mean
differences (SMD) and 95% conﬁdence intervals (95%CI) were calculated
for paired samples using within-patient pre-intervention and post-
intervention means and standard deviations. For patient-reported
outcome measures in high quality randomized trials that compared a
valgus knee brace treatment group to a control group, SMD and 95%CI
were calculated using post-intervention means, standard deviations
and/or effect sizes.
Results: Thirty-eight studies were included (n ¼ 1098). Data from 16
studies were pooled in meta-analyses. Biomechanical studies suggested
a moderate, signiﬁcant decrease in the external knee adduction
moment (SMD¼0.61; 95%CI: 0.39, 0.83; p < 0.001; I2¼40.8, p ¼ 0.06)
(Figure 1) and knee adduction angular impulse during walking
(SMD¼0.77; 95%CI: 0.32, 1.23; p < 0.001; I2¼56.3, p ¼ 0.08). Random-
ized clinical trials suggested moderate, signiﬁcant improvements in
pain (SMD¼0.46; 95%CI: 0.09, 0.83; p ¼ 0.014; I2¼35.5, p ¼ 0.21) and
function (SMD¼0.39; 95%CI: 0.10, 0.68; p ¼ 0.008; I2¼0.0, p ¼ 0.44).
Studies that reported brace parameters inﬂuencing dosage were
inconsistent and unclear. No studies evaluated structural measures of
disease progression or cost of bracing. Signiﬁcant heterogeneity pre-
vented pooling of complications data. Complications reported during
brace use were slipping, discomfort and poor ﬁt, mechanical brace
problems, heat, heaviness, skin irritation, blisters and swelling. Patient-
reported brace use varied considerably between studies, but con-
sistently decreased over time.
Conclusions: This systematic review and meta-analysis of the pub-
lished literature is the ﬁrst to quantify effect sizes for valgus knee
braces. Results on biomechanical effects and clinical outcomes supports
the use of valgus knee braces in the management of medial knee OA;
however, issues related to their appropriate dosage, patient comfort and
compliance remain as substantial challenges to long-term use. Identi-
ﬁed gaps in the literature include optimal dosage, characteristics of
those who respond best, effects on disease progression, and economic
evaluations.
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GOOD LIFE WITH ARTHRITIS IN DENMARK (GLA:D) -
IMPLEMENTATION OF EVIDENCE-BASED CARE FOR KNEE AND HIP
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Purpose: To introduce a nationwide initiative in Denmark (Good Life
with Arthritis in Denmark (GLA:D)) aimed at implementing interna-
tional guidelines for knee and hip osteoarthritis (OA) and evaluate the
short-term and long-term effectiveness of a pilot study.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S458Methods: GLA:D is a non-surgical treatment program for patients with
knee and hip OA. It consists of three 1.5-hour sessions of patient edu-
cation and 12 sessions of individualized, physiotherapist supervised
neuromuscular exercise according to the NEuroMuscular EXercise
program (NEMEX) (Ageberg 2010). The GLA:D concept is taught to the
physiotherapists during a two-day course (ﬁrst course held in January
2013). Furthermore, GLA:D is a registry holding data from the baseline
assessment and from the 3 months and 12 months follow-ups of all
patients entering GLA:D.
A pilot study was performed in a physiotherapy clinic in Denmark
including 79 patients with knee and/or hip OA (67 women; mean age
(SD) 62.4 (7.2); mean pain intensity (VAS 0-100, SD) 42.4 (18.9); mean
BMI (SD) 28.4 (7.8)). In the pilot study, Pain (VAS 0-100, primary out-
come), Euro-Quality-of-Life - 5 Dimensional form (EQ- 5D) and body
mass index (BMI) were evaluated at baseline and after 3 and 12months.
Furthermore, compliance was registered as general adherence to the
treatment program at the 12 months follow-up on a ﬁve-point scale
(never, every month, every week, every day, several times a day).
Additionally, the participants were asked to rate their opinion of GLA:D
on a ﬁve-point scale (very bad, bad, neither bad nor good, good, very
good).
Results: GLA:D is now (November 2013) offered at 49 units in both
primary and secondary care and across all 5 health care regions in
Denmark. More than 600 patients have entered data into the registry.
Due to a huge interest among patients, health care providers and the
media, these numbers are rising exponentially.
In the pilot study, 78 participants (99%) completed the 12 months fol-
low-up. Signiﬁcant improvements (p < 0.001) were found in the pri-
mary outcome pain from baseline to the 3 months (-13.0mm) and 12
months (-11.4 mm) follow-ups and in EQ-5D from baseline to the 3
months (0.05) and 12 months (0.05) follow-ups. At the 12 months fol-
low-up, 56 participants (72%) were using what they had learned at least
every week and only six (8%) never used it. 72 participants (92%) rated
the GLA:D concept as good or very good.
Conclusions: The GLA:D concept is feasible, in terms of health care
providers being willing to pay for a two-day education, the program
being available across the country, and patients and therapists being
able and willing to enter data into the registry. The pilot study dem-
onstrated that the treatment program reduced pain and increased
quality of life in patients with knee and hip OA and that the
improvements persisted 9 months after the intervention ended con-
ﬁrming long-term effects. Teaching content of clinical guidelines to
physiotherapists and providing a free of charge registry for data col-
lection increase the quality of care provided for patients with knee and
hip OA.
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MULTI-MODAL PHYSIOTHERAPY AND HIGH TIBIAL OSTEOTOMY CAN
MITIGATE RISK FACTORS FOR DISEASE PROGRESSION IN PATIENTS
WITH VARUS GONARTHROSIS
A. Boulougouris y,z, T.B. Birmingham y,z, T.D. Olver y,x, K. Leitch y,z,
P. Lemon y,x, J.R. Gifﬁn y,z. yWestern Univ., London, ON, Canada; zWolf
Orthopaedic Biomechanics Labratory, London, ON, Canada; x Exercise
Nutrition and Res. Lab., London, ON, Canada
Purpose: Rehabilitative interventions for patients with knee osteo-
arthritis (OA) can substantially decrease body mass and increase mus-
cular strength, but have limited effects on limb mal-alignment. High
tibial osteotomy (HTO) can effectively correct mal-alignment, but can
also lead to increased body mass and decreased muscular strength. The
primary objective of the present study was to investigate the cumu-
lative effects of combined physiotherapy and medial opening wedge
HTO in patients with varus gonarthrosis.
Methods: In this proof of principle study, eight patients with varus mal-
alignment and medial compartment knee OA completed a multi-modal
intervention consisting of medial opening wedge HTO and 8-weeks of
rehabilitation with a focus on reducing fat mass and increasing mus-
cular strength (multi-modal physiotherapy, MPT) repeated approx-
imately 4 months before and 12 months after surgery. Outcomes
included measures of body composition, isokinetic strength, radio-
graphic lower limb alignment, the external knee adduction moment
during walking, and the Knee injury and Osteoarthritis Outcome Score
(KOOS).
Results: Repeated measures analysis of variance indicated signiﬁcant (p
< 0.05) changes over time for all outcome measures with the exceptionof lean mass. Mean changes (95%CI) from the study baseline to its
endpoint indicated that, overall, patients lost substantial fat mass [4.6
kg (-8.0, -1.2)], made modest improvements in isokinetic knee exten-
sion peak torque [7.2Nm (-45.0, 59.5)] and knee ﬂexion peak torque
[23.0Nm (-1.8, 47.7)], had mal-alignment corrected from substantial
varus to approximately neutral [8.6 (6.3, 10.8)], and experienced very
large improvements in the peak knee adduction moment during
walking [-27.7Nm (-43.1, -11.6)] and in the KOOS [e.g., improvement in
pain domain ¼ 31.4 (10.0, 52.8)].
Conclusions: The present ﬁndings support the principle of using multi-
modal rehabilitative and surgical interventions that target different risk
factors to produce overall, cumulative beneﬁts for patients with varus
gonarthrosis. Moreover, the MPT was required to produce the
improvements in body composition and strength, whereas the HTOwas
required to produce the improvements in alignment and knee adduc-
tion moment.
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IMPORTANCE OF ADHERENCE IN OUTCOME OF EXERCISE THERAPY
IN PATIENTS WITH KNEE OSTEOARTHRITIS
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Purpose: This study aims to determine associations of various adher-
ence variables with outcome of exercise therapy in knee osteoarthritis
(OA), separately for the treatment and post-treatment period.
Methods: One hundred ﬁfty nine patients with knee OA participated a
randomized, controlled trial (STABILITY; NTR1492) in which two 12-
week exercise programs were found to be similarly effective. For the
present study, adherence during treatment was operationalized as the
number of attended sessions (attendance) and the number of days
performing home exercises during treatment (home exercise adher-
ence), while adherence post-treatment was operationalized as the
number of days performing home exercises post-treatment (post-
treatment home exercise adherence) or performing other sports
activities (post-treatment sports activity adherence). Finally, a summed
overall adherence score which includes all adherence variables was
calculated. Outcome measures were WOMAC physical function, NRS
pain, the Get up and Go test, isometric upper leg muscle strength, and
patient-reported knee instability. Regression analysis was used to
determine associations between adherence and outcome, separately for
the treatment period (baseline to 12-week follow-up), post-treatment
period (12 to 38-week follow-up) and the total period (baseline to 38-
week follow-up), adjusting for treatment group and demographics.
Results: Both attendance (but only for WOMAC physical function) and
home exercise adherence (for WOMAC physical function, pain, and
muscle strength) were signiﬁcantly associated with outcome in the
treatment period. No associations were found between post-treatment
home exercise adherence or sports activity adherence with outcome in
